vs
华美银行集团（EWBC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
华美银行集团的季度营收约是Revvity的1.0倍（$775.0M vs $772.1M），华美银行集团净利率更高（46.2% vs 12.7%，领先33.5%），Revvity同比增速更快（5.9% vs 2.1%），过去两年华美银行集团的营收复合增速更高（18.4% vs 9.0%）
华美银行集团旗下核心子公司为华美银行，是总部位于美国南加州的最大上市银行控股集团。集团资产规模超100亿美元，曾获评标普全球市场财智全美最佳银行，自2023年起连续三年位列《银行董事》杂志同资产规模银行绩效榜单首位。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
EWBC vs RVTY — 直观对比
营收规模更大
EWBC
是对方的1.0倍
$772.1M
营收增速更快
RVTY
高出3.7%
2.1%
净利率更高
EWBC
高出33.5%
12.7%
两年增速更快
EWBC
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $775.0M | $772.1M |
| 净利润 | $358.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 46.2% | 12.7% |
| 营收同比 | 2.1% | 5.9% |
| 净利润同比 | 0.4% | 3.9% |
| 每股收益（稀释后） | $2.57 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWBCRVTY
| Q1 26 | $775.0M | — | ||
| Q4 25 | $657.8M | $772.1M | ||
| Q3 25 | $677.5M | $698.9M | ||
| Q2 25 | $617.1M | $720.3M | ||
| Q1 25 | $600.2M | $664.8M | ||
| Q4 24 | $587.6M | $729.4M | ||
| Q3 24 | $572.7M | $684.0M | ||
| Q2 24 | $553.2M | $691.7M |
净利润EWBCRVTY
| Q1 26 | $358.0M | — | ||
| Q4 25 | $356.3M | $98.4M | ||
| Q3 25 | $368.4M | $46.7M | ||
| Q2 25 | $310.3M | $53.9M | ||
| Q1 25 | $290.3M | $42.2M | ||
| Q4 24 | $293.1M | $94.6M | ||
| Q3 24 | $299.2M | $94.4M | ||
| Q2 24 | $288.2M | $55.4M |
毛利率EWBCRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率EWBCRVTY
| Q1 26 | — | — | ||
| Q4 25 | 71.0% | 14.5% | ||
| Q3 25 | 68.6% | 11.7% | ||
| Q2 25 | 65.2% | 12.6% | ||
| Q1 25 | 65.2% | 10.9% | ||
| Q4 24 | 60.6% | 16.3% | ||
| Q3 24 | 68.0% | 14.3% | ||
| Q2 24 | 65.9% | 12.4% |
净利率EWBCRVTY
| Q1 26 | 46.2% | — | ||
| Q4 25 | 54.2% | 12.7% | ||
| Q3 25 | 54.4% | 6.7% | ||
| Q2 25 | 50.3% | 7.5% | ||
| Q1 25 | 48.4% | 6.4% | ||
| Q4 24 | 49.9% | 13.0% | ||
| Q3 24 | 52.2% | 13.8% | ||
| Q2 24 | 52.1% | 8.0% |
每股收益（稀释后）EWBCRVTY
| Q1 26 | $2.57 | — | ||
| Q4 25 | $2.55 | $0.86 | ||
| Q3 25 | $2.65 | $0.40 | ||
| Q2 25 | $2.24 | $0.46 | ||
| Q1 25 | $2.08 | $0.35 | ||
| Q4 24 | $2.10 | $0.77 | ||
| Q3 24 | $2.14 | $0.77 | ||
| Q2 24 | $2.06 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.0B | $7.3B |
| 总资产 | $82.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EWBCRVTY
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | $919.9M | ||
| Q3 25 | $4.7B | $931.4M | ||
| Q2 25 | $4.4B | $991.8M | ||
| Q1 25 | $3.4B | $1.1B | ||
| Q4 24 | $5.3B | $1.2B | ||
| Q3 24 | $4.9B | $1.2B | ||
| Q2 24 | $4.4B | $2.0B |
总债务EWBCRVTY
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | — | ||
| Q3 25 | $35.7M | — | ||
| Q2 25 | $35.8M | — | ||
| Q1 25 | $35.9M | — | ||
| Q4 24 | $36.0M | — | ||
| Q3 24 | $36.1M | — | ||
| Q2 24 | $36.1M | — |
股东权益EWBCRVTY
| Q1 26 | $9.0B | — | ||
| Q4 25 | $8.9B | $7.3B | ||
| Q3 25 | $8.6B | $7.4B | ||
| Q2 25 | $8.2B | $7.6B | ||
| Q1 25 | $7.9B | $7.6B | ||
| Q4 24 | $7.7B | $7.7B | ||
| Q3 24 | $7.7B | $7.9B | ||
| Q2 24 | $7.2B | $7.9B |
总资产EWBCRVTY
| Q1 26 | $82.9B | — | ||
| Q4 25 | $80.4B | $12.2B | ||
| Q3 25 | $79.7B | $12.1B | ||
| Q2 25 | $78.2B | $12.4B | ||
| Q1 25 | $76.2B | $12.4B | ||
| Q4 24 | $76.0B | $12.4B | ||
| Q3 24 | $74.5B | $12.8B | ||
| Q2 24 | $72.5B | $13.4B |
负债/权益比EWBCRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流EWBCRVTY
| Q1 26 | — | — | ||
| Q4 25 | $713.4M | $182.0M | ||
| Q3 25 | $231.7M | $138.5M | ||
| Q2 25 | $278.7M | $134.3M | ||
| Q1 25 | $277.9M | $128.2M | ||
| Q4 24 | $500.1M | $174.2M | ||
| Q3 24 | $386.1M | $147.9M | ||
| Q2 24 | $259.2M | $158.6M |
自由现金流EWBCRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率EWBCRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度EWBCRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% |
现金转化率EWBCRVTY
| Q1 26 | — | — | ||
| Q4 25 | 2.00× | 1.85× | ||
| Q3 25 | 0.63× | 2.97× | ||
| Q2 25 | 0.90× | 2.49× | ||
| Q1 25 | 0.96× | 3.03× | ||
| Q4 24 | 1.71× | 1.84× | ||
| Q3 24 | 1.29× | 1.57× | ||
| Q2 24 | 0.90× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EWBC
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
